AndroGel Pediatric Safety (Under Age 12): What Parents and Clinicians Must Know

Why AndroGel Is Never Prescribed to Children Under 12

AndroGel is a prescription-only topical testosterone approved by the FDA solely for adult males with hypogonadism confirmed by clinical signs and two morning serum testosterone measurements below 300 ng/dL. Children under 12 have no approved indication for this formulation, and the prescribing information issued by AbbVie lists pediatric exposure as a contraindication for household members, not just patients.

The concern is not theoretical. Testosterone is a potent androgen at doses far below what adults require for therapeutic effect. A child's hypothalamic-pituitary-gonadal axis is suppressed until puberty, and even small amounts of exogenous androgen can trigger premature activation of androgen receptors in bone, skin, and genital tissue. The FDA's 2009 black-box warning update specifically cited case reports of children developing pubic hair, clitoral or penile enlargement, and advanced bone age after living with adults using testosterone gels, including the AndroGel 1% formulation. [1]

Because accidental pediatric exposure happens in the home rather than a clinical setting, underreporting is common. The FDA MedWatch database has logged dozens of pediatric secondary exposure cases tied to topical testosterone products since 2000, a number the agency considers an undercount. [2]

How Skin-to-Skin Transfer Works

Testosterone gel dries on the skin surface within minutes, but a residual film of active drug remains transferable for hours unless the site is covered or washed. The mechanism is straightforward: an adult applies AndroGel to the shoulders, upper arms, or abdomen; residual gel on the skin contacts a child's skin during hugging, carrying, or co-sleeping; and testosterone crosses the child's thinner, more permeable epidermal barrier.

Studies using the 1% gel formulation showed that a single uncovered skin-to-skin contact event transferred measurable testosterone to a partner's skin, with detectable serum elevations in some subjects within 24 hours. [3] Covering the application site with a T-shirt reduced transfer by approximately 95% in pharmacokinetic studies cited in the AndroGel prescribing information. [4] Washing the application site with soap and water before contact provided similar protection.

Children's skin is thinner and has a higher surface-area-to-body-weight ratio than adult skin, meaning that the same quantity of transferred testosterone produces a proportionally higher systemic dose in a 20 kg child than in a 70 kg adult. [5] This pharmacokinetic reality is why the FDA classifies children as a specifically vulnerable population for topical androgen products.

FDA Black-Box Warning: Exact Language and What It Requires

The FDA black-box warning in the AndroGel prescribing information states that virilization has been reported in children who were secondarily exposed to testosterone gel. The warning mandates that:

1. Patients wash their hands immediately after applying the gel.
2. Patients cover the application site with clothing after the gel dries.
3. Patients shower before anticipated skin-to-skin contact if covering is not possible.
4. The gel should never be applied to the scrotum or skin areas that a child is likely to contact.

The FDA issued a drug safety communication in 2009 and a follow-up MedWatch alert reinforcing these precautions after reviewing 20 pediatric cases, 19 of which involved secondary exposure from a household member's topical testosterone. [2] The Endocrine Society's clinical practice guideline on male hypogonadism, updated in 2018, echoes these precautions and notes that "household members, especially children and pregnant women, should avoid contact with testosterone gel application sites." [6]

The table below summarizes the specific handling steps that the FDA and the AndroGel label require, organized by timing relative to application. Clinicians prescribing AndroGel should review this framework with patients at every visit when children or pregnant individuals are in the household.

Clinician-Recommended Exposure-Prevention Framework for Households with Children Under 12

| Timing | Required Action | Evidence Basis | |---|---|---| | Immediately after application | Wash hands with soap and water | AndroGel PI, Section 2.2 | | Within 2 minutes of application | Cover site with clothing (T-shirt) | FDA 2009 Drug Safety Communication | | Before child contact (if uncovered) | Shower and wash application site | AndroGel PI black-box warning | | If child shows early virilization signs | Stop adult's gel use; refer child to pediatric endocrinology | Endocrine Society 2018 GL |

Signs of Secondary Virilization in Children Under 12

Parents and pediatricians should recognize these clinical signs, because early identification and elimination of the exposure source can prevent lasting harm. The most commonly reported findings in published pediatric secondary exposure cases are pubic or axillary hair growth, clitoral or penile enlargement, acne, aggressive behavior, and accelerated linear growth. [7]

Advanced bone age is the complication that receives the least public attention and carries the most long-term consequence. Testosterone accelerates the fusion of epiphyseal growth plates. A child exposed repeatedly over several months may gain bone age that cannot be reversed even after the exposure stops, potentially reducing adult height. [8] One published case series described a 4-year-old boy who developed pubic hair and a bone age of 8 years after 14 months of contact with his father's application sites. Bone-age advancement persisted at 6-month follow-up despite cessation of exposure. [9]

Soft-tissue changes such as pubic hair and genital enlargement typically regress within 3 to 6 months after the child is no longer exposed. [7] Regression of bone-age acceleration does not follow the same timeline and should be tracked with serial hand-and-wrist radiographs every 6 months in any child confirmed to have had prolonged androgen exposure. [8]

What the T-Trials Tell Us About Topical Testosterone Pharmacology

The Testosterone Trials (T-Trials) were a coordinated set of seven placebo-controlled trials in 788 men aged 65 or older with low testosterone (serum testosterone <275 ng/dL on two morning measurements). Published in 2016, the T-Trials used a 1.62% testosterone gel applied daily and confirmed that topical testosterone raises serum testosterone into the normal adult male range (300 to 1 to 000 ng/dL) with consistent daily use. [10] The T-Trials were not designed to study pediatric safety, but their pharmacokinetic data reinforced two points directly relevant to child-safety concerns: first, the gel produces sustained supraphysiologic skin-surface concentrations for several hours post-application; and second, even within the adult study population, serum testosterone levels varied substantially based on application technique and body site. [10]

These findings matter for pediatric safety because they confirm that the gel's dermal reservoir is substantial enough to transfer biologically active testosterone to a second person for an extended window after application, not just in the first few minutes. Clinicians counseling households with young children should emphasize that the danger period extends well beyond the initial drying time. [3]

Bone Age, Growth Plates, and Why Timing Matters

Children under 12 are in a period of active skeletal development. The long bones grow via endochondral ossification at the epiphyseal growth plates, a process regulated by growth hormone and insulin-like growth factor 1, but also highly sensitive to sex steroids. Even brief androgen surges can accelerate the rate of plate maturation. [8]

Pediatric endocrinologists use the Greulich-Pyle atlas or the Tanner-Whitehouse method to read bone age from hand-and-wrist radiographs. A bone age more than 2 standard deviations above chronological age in a child with no constitutional tall stature or precocious puberty diagnosis should prompt investigation into androgen exposure. [11] The American Academy of Pediatrics' clinical report on precocious puberty lists exogenous androgen exposure as a recognized cause of gonadotropin-independent precocious puberty and recommends removal of the exposure source as the first clinical step. [12]

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels will typically be suppressed in exogenous androgen exposure, because the hypothalamus detects high circulating androgens and reduces gonadotropin-releasing hormone (GnRH) pulse frequency. [11] This suppressed LH/FSH pattern distinguishes secondary androgen exposure from central precocious puberty, where LH and FSH are elevated. Checking basal LH, FSH, and total testosterone in a child showing virilization signs can rapidly distinguish these two diagnoses. [12]

Regulatory History and FDA Actions Specific to Pediatric Safety

The FDA's concern about pediatric exposure to topical testosterone predates the current AndroGel black-box warning. In 2000, the agency first approved testosterone gel products with language about avoiding transfer. By 2009, accumulating case reports prompted a formal Drug Safety Communication and mandatory label revisions across all topical testosterone products, including AndroGel 1%, AndroGel 1.62%, Testim, Axiron, and Fortesta. [2]

In 2011, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) for all topical testosterone gel products. The REMS required manufacturers to provide a Medication Guide and a Patient Instructions for Use document specifically addressing pediatric exposure risks. [13] AbbVie's REMS for AndroGel included mandatory patient counseling elements that prescribers are required to complete at the time of prescribing. Failure to provide this counseling is a REMS non-compliance issue. [13]

The FDA's 2014 safety announcement broadened the concern by questioning whether cardiovascular risks in adults warranted new label warnings, but the pediatric secondary-exposure language was retained and strengthened in the 2015 label revision. [14] That revision added explicit guidance that patients with children in the home should consider non-gel testosterone formulations (intramuscular injections, subcutaneous pellets) to eliminate transfer risk entirely. [14]

Alternative Testosterone Formulations That Eliminate Transfer Risk

For adult males with hypogonadism who have children under 12 at home, the safest approach from a transfer-risk standpoint is a non-topical testosterone formulation. Testosterone cypionate and testosterone enanthate, both injectable formulations administered intramuscularly every 1 to 2 weeks (or more frequently at lower doses), produce no skin-surface reservoir and carry zero transfer risk. [15]

Testosterone pellets (brand name Testopel) implanted subcutaneously every 3 to 6 months also carry no topical transfer risk. Subcutaneous testosterone cypionate at doses of 50 to 100 mg weekly, delivered via insulin syringe, is increasingly used in hormone clinics and eliminates household exposure concerns entirely. [15]

If a patient strongly prefers topical delivery, testosterone patches (Androderm) transfer testosterone at a lower rate than gel formulations because the drug is contained within a membrane system rather than applied as an open film. However, patches are not zero-risk; the FDA label still advises covering the patch site when children will have skin contact. [16]

Nasal testosterone gel (Natesto, 11 mg per nostril three times daily) avoids skin-surface transfer because it is applied intranasally. The nasal mucosa does not present a contact-transfer surface under normal household conditions, making Natesto a reasonable option for fathers with young children, provided its lower peak testosterone levels and more variable pharmacokinetics are acceptable. [17]

Counseling Checklist for Prescribers

Before writing an AndroGel prescription for any patient with a child under 12 in the household, the prescribing clinician should address each of the following points and document the discussion in the medical record:

1. Confirm the patient understands the black-box warning and can repeat back the three prevention steps (hand washing, covering, showering).
2. Assess whether a non-topical formulation would be equally acceptable clinically and less hazardous given the household composition.
3. Provide the FDA-required Medication Guide and document its provision.
4. Ask whether any household member, including a child or pregnant partner, has shown any signs of unexpected virilization or androgen effect.
5. Schedule a follow-up within 90 days to reassess both adult testosterone levels and household safety adherence.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states directly that clinicians "should advise patients about the risk of secondary exposure to testosterone and explain methods to minimize exposure of women and children." [6] Documentation of this counseling protects the patient and the prescriber.

What to Do If a Child Shows Signs of Exposure

Prompt action stops the process. If a child under 12 shows any sign of unexpected sexual development, including pubic hair, genital enlargement, acne, or accelerated growth, the adult's AndroGel use should be paused immediately while the child is evaluated. The child's pediatrician or a pediatric endocrinologist should obtain:

• Serum total testosterone (morning sample, Tanner stage noted)
• Basal LH and FSH
• Bone age (hand-and-wrist radiograph, read against Greulich-Pyle norms)
• DHEAS and 17-hydroxyprogesterone to exclude adrenal causes [11]

If serum testosterone is elevated and LH and FSH are suppressed, exogenous androgen exposure is the leading diagnosis. Reporting to FDA MedWatch (1-800-FDA-1088 or online at fda.gov/safety/medwatch) is encouraged and supports ongoing pharmacovigilance. [2]

The adult's testosterone therapy should be switched to a non-topical formulation or the AndroGel application and safety protocol should be completely revised before resumption, with documented re-counseling in the chart. Testosterone levels in the child will typically return to age-appropriate (prepubertal) values within 4 to 12 weeks of cessation. [7] Bone-age monitoring should continue every 6 months for at least 24 months.